

Delia Goletti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1609954/publications.pdf>

Version: 2024-02-01

275
papers

20,636
citations

11651

70
h-index

12597

132
g-index

279
all docs

279
docs citations

279
times ranked

28190
citing authors

#	ARTICLE	IF	CITATIONS
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. <i>Clinical Infectious Diseases</i> , 2023, 76, e426-e438.	5.8	23
2	Coordinated cellular and humoral immune responses after two-dose SARS-CoV2 mRNA vaccination in liver transplant recipients. <i>Liver International</i> , 2022, 42, 180-186.	3.9	36
3	Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies. <i>Neurology</i> , 2022, 98, .	1.1	125
4	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	3.4	20
5	VIDAS [®] TB-IGRA reagents induce a CD4 ⁺ and CD8 ⁺ T-cell IFN- γ response for both TB infection and active TB. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 65-68.	1.2	7
6	Practices of therapeutic drug monitoring in tuberculosis: an international survey. <i>European Respiratory Journal</i> , 2022, 59, 2102787.	6.7	11
7	Assay design for unambiguous identification and quantification of circulating pathogen-derived peptide biomarkers. <i>Theranostics</i> , 2022, 12, 2948-2962.	10.0	3
8	Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2022, 13, 846753.	4.8	37
9	Armed conflict and human displacement may lead to an increase in the burden of tuberculosis in Europe. <i>International Journal of Infectious Diseases</i> , 2022, 124, S104-S106.	3.3	10
10	In-Depth Immunophenotyping With Mass Cytometry During TB Treatment Reveals New T-Cell Subsets Associated With Culture Conversion. <i>Frontiers in Immunology</i> , 2022, 13, 853572.	4.8	5
11	Clinical standards for the diagnosis, treatment and prevention of TB infection. <i>International Journal of Tuberculosis and Lung Disease</i> , 2022, 26, 190-205.	1.2	29
12	World TB Day 2022: Revamping and Reshaping Global TB Control Programs by Advancing Lessons learnt from the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2022, 124, S1-S3.	3.3	15
13	Commemorating World Tuberculosis Day 2022: recent <i>ERJ</i> articles of critical relevance to ending TB and saving lives. <i>European Respiratory Journal</i> , 2022, 59, 2200149.	6.7	0
14	Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study. <i>Journal of Infection</i> , 2022, 84, 834-872.	3.3	8
15	The role of antibodies in tuberculosis diagnosis, prophylaxis and therapy: a review from the ESGMYC study group. <i>European Respiratory Review</i> , 2022, 31, 210218.	7.1	15
16	Increased Association of Pulmonary Thromboembolism and Tuberculosis during COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. <i>Antibiotics</i> , 2022, 11, 398.	3.7	3
17	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. <i>International Journal of Infectious Diseases</i> , 2022, 124, S12-S19.	3.3	42
18	Country-specific approaches to latent tuberculosis screening targeting migrants in EU/EEA* countries: A survey of national experts, September 2019 to February 2020. <i>Eurosurveillance</i> , 2022, 27, .	7.0	3

#	ARTICLE	IF	CITATIONS
19	Platelets accumulate in lung lesions of tuberculosis patients and inhibit T cell responses and <i>Mycobacterium tuberculosis</i> replication in macrophages. <i>European Journal of Immunology</i> , 2022, 52, 784-799.	2.9	6
20	Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy. <i>Cells</i> , 2022, 11, 52.	4.1	11
21	Tailored first-line biologic and targeted synthetic disease modifying anti-rheumatic drugs therapy in patients with rheumatoid arthritis: 2021 updated ITABIO statements. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 613-623.	2.4	3
22	Humoral and cellular responses to spike of Î SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases. <i>International Journal of Infectious Diseases</i> , 2022, 121, 24-30.	3.3	21
23	Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine. <i>Scientific Reports</i> , 2022, 12, 6687.	3.3	31
24	Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. <i>European Respiratory Journal</i> , 2022, 59, 2200388.	6.7	15
25	Country-specific lockdown measures in response to the COVID-19 pandemic and its impact on tuberculosis control: a global study. <i>Jornal Brasileiro De Pneumologia</i> , 2022, 48, e20220087.	0.7	10
26	Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, .	2.4	18
27	Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants. <i>Cell Death Discovery</i> , 2022, 8, .	4.7	12
28	COVID-19 effects on tuberculosis care in Sierra Leone. <i>Pulmonology</i> , 2021, 27, 67-69.	2.1	50
29	A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 286.e7-286.e13.	6.0	104
30	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. <i>Science Advances</i> , 2021, 7, .	10.3	176
31	TB and COVID-19 co-infection: rationale and aims of a global study. <i>International Journal of Tuberculosis and Lung Disease</i> , 2021, 25, 78-80.	1.2	22
32	Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome. <i>International Journal of Infectious Diseases</i> , 2021, 103, 607-610.	3.3	9
33	Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. <i>Antibiotics</i> , 2021, 10, 272.	3.7	60
34	Inhibition of HECT E3 ligases as potential therapy for COVID-19. <i>Cell Death and Disease</i> , 2021, 12, 310.	6.3	33
35	World Tuberculosis Day 2021 Theme "The Clock is Ticking" and the world is running out of time to deliver the United Nations General Assembly commitments to End TB due to the COVID-19 pandemic. <i>International Journal of Infectious Diseases</i> , 2021, 113, S1-S6.	3.3	10
36	Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2021, 113, S82-S87.	3.3	64

#	ARTICLE	IF	CITATIONS
37	Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects. <i>Pulmonology</i> , 2021, 27, 151-165.	2.1	172
38	Baricitinib Therapy in Covid-19 Pneumonia – An Unmet Need Fulfilled. <i>New England Journal of Medicine</i> , 2021, 384, 867-869.	27.0	56
39	PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease. <i>Frontiers in Immunology</i> , 2021, 12, 594376.	4.8	11
40	In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. <i>Journal of Infection</i> , 2021, 82, 58-66.	3.3	44
41	Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 106, 338-347.	3.3	43
42	Transglutaminase 2 Regulates Innate Immunity by Modulating the STING/TBK1/IRF3 Axis. <i>Journal of Immunology</i> , 2021, 206, 2420-2429.	0.8	13
43	Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2388.	2.4	17
44	Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach. <i>International Journal of Infectious Diseases</i> , 2021, 107, 247-250.	3.3	38
45	Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. <i>Journal of Translational Medicine</i> , 2021, 19, 272.	4.4	19
46	Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine. <i>Microorganisms</i> , 2021, 9, 1315.	3.6	54
47	Impact of Prior Influenza and Pneumococcal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination. <i>Vaccines</i> , 2021, 9, 615.	4.4	15
48	In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses. <i>BioMed Research International</i> , 2021, 2021, 1-21.	1.9	9
49	The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1784-1789.	6.0	54
50	Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring. <i>Scientific Reports</i> , 2021, 11, 13646.	3.3	20
51	Common and Rare Hematological Manifestations and Adverse Drug Events during Treatment of Active TB: A State of Art. <i>Microorganisms</i> , 2021, 9, 1477.	3.6	16
52	Antibody Subclass and Glycosylation Shift Following Effective TB Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 679973.	4.8	22
53	Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009648.	3.0	6
54	Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	38

#	ARTICLE	IF	CITATIONS
55	Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease. <i>Frontiers in Immunology</i> , 2021, 12, 716857.	4.8	6
56	Initiation and completion of treatment for latent tuberculosis infection in migrants globally: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1701-1712.	9.1	32
57	Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study. <i>European Respiratory Journal</i> , 2021, 58, 2101786.	6.7	86
58	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. <i>Breathe</i> , 2021, 17, 210079.	1.3	59
59	Immunosuppressive Therapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 740249.	4.8	70
60	Concurrent cavitory pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy. <i>Infection</i> , 2021, 49, 1061-1064.	4.7	18
61	Pathogenesis and Immunology of Tuberculosis. , 2021, , 19-27.		1
62	Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. <i>Frontiers in Immunology</i> , 2021, 12, 725447.	4.8	25
63	Making IGRA testing easier: First performance report of QIArearch QFT for tuberculosis infection diagnosis. <i>Pulmonology</i> , 2021, 28, 4-4.	2.1	8
64	Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. <i>Frontiers in Public Health</i> , 2021, 9, 666187.	2.7	2
65	Identification of Recent Tuberculosis Exposure Using QuantiFERON-TB Gold Plus, a Multicenter Study. <i>Microbiology Spectrum</i> , 2021, 9, e0097221.	3.0	6
66	Multi-omics approach to COVID-19: a domain-based literature review. <i>Journal of Translational Medicine</i> , 2021, 19, 501.	4.4	18
67	Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. <i>International Journal of Infectious Diseases</i> , 2020, 92, 62-68.	3.3	13
68	The impact of the interleukin 12/23 inhibitor ustekinumab on the risk of infections in patients with psoriatic arthritis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 69-82.	2.4	10
69	Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections. <i>Apmis</i> , 2020, 128, 92-103.	2.0	64
70	Species specificity preliminary evaluation of an IL-4 based test for the differential diagnosis of human echinococcosis. <i>Parasite Immunology</i> , 2020, 42, e12695.	1.5	9
71	Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review. <i>Drugs</i> , 2020, 80, 1929-1946.	10.9	74
72	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	4.3	133

#	ARTICLE	IF	CITATIONS
73	Multicenter analysis of sputum microbiota in tuberculosis patients. <i>PLoS ONE</i> , 2020, 15, e0240250.	2.5	10
74	What is the role of the EUCAST reference method for MIC testing of the <i>Mycobacterium tuberculosis</i> complex?. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1453-1455.	6.0	14
75	Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries?. <i>Frontiers in Public Health</i> , 2020, 8, 443.	2.7	5
76	Association of baseline white blood cell counts with tuberculosis treatment outcome: a prospective multicentered cohort study. <i>International Journal of Infectious Diseases</i> , 2020, 100, 199-206.	3.3	32
77	Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. <i>Journal of Infectious Diseases</i> , 2020, 222, 1807-1815.	4.0	167
78	Impact of the global COVID-19 outbreak on the management of other communicable diseases. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 547-548.	1.2	21
79	Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts. <i>Pulmonology</i> , 2020, 26, 233-240.	2.1	178
80	Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. <i>European Respiratory Journal</i> , 2020, 56, 2001398.	6.7	273
81	Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 861-872.	2.4	24
82	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. <i>Molecular Immunology</i> , 2020, 120, 187-195.	2.2	19
83	Commemorating World TB Day 2020: "It's time to End the Global TB Epidemic". <i>International Journal of Infectious Diseases</i> , 2020, 92, S1-S4.	3.3	6
84	Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. <i>Journal of Infection</i> , 2020, 81, 647-679.	3.3	155
85	On tuberculosis and COVID-19 co-infection. <i>European Respiratory Journal</i> , 2020, 56, 2002328.	6.7	93
86	Epidemic and pandemic viral infections: impact on tuberculosis and the lung. <i>European Respiratory Journal</i> , 2020, 56, 2001727.	6.7	89
87	Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection. <i>Journal of Infection</i> , 2020, 80, 536-546.	3.3	38
88	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	3.3	26
89	Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. <i>European Respiratory Journal</i> , 2020, 55, 1901957.	6.7	30
90	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126

#	ARTICLE	IF	CITATIONS
91	Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. <i>Journal of Infection</i> , 2020, 81, 318-356.	3.3	358
92	Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon- γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study. <i>Frontiers in Immunology</i> , 2020, 11, 616450.	4.8	22
93	The Mycobacterial HBHA Protein: A Promising Biomarker for Tuberculosis. <i>Current Medicinal Chemistry</i> , 2019, 26, 2051-2060.	2.4	14
94	Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry. <i>European Journal of Histochemistry</i> , 2019, 63, .	1.5	8
95	QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. <i>Journal of Infection</i> , 2019, 79, 444-453.	3.3	64
96	IP-10 contributes to the inhibition of mycobacterial growth in an ex vivo whole blood assay. <i>International Journal of Medical Microbiology</i> , 2019, 309, 299-306.	3.6	14
97	Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 415-425.	2.4	33
98	Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy. <i>PLoS ONE</i> , 2019, 14, e0212948.	2.5	22
99	Characterization of QuantiFERON-TB-Plus results in latent tuberculosis infected patients with or without immune-mediated inflammatory diseases. <i>Journal of Infection</i> , 2019, 79, 15-23.	3.3	16
100	Global tuberculosis prevention: should we start from the beginning?. <i>European Respiratory Journal</i> , 2019, 54, 1901394.	6.7	9
101	Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis. <i>BMC Infectious Diseases</i> , 2019, 19, 882.	2.9	14
102	Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 169-177.	6.0	35
103	Severe chest allodynia as an unusual first presentation of hydatid disease: a case report. <i>BMC Infectious Diseases</i> , 2019, 19, 37.	2.9	0
104	First description of agonist and antagonist IP-10 in urine of patients with active TB. <i>International Journal of Infectious Diseases</i> , 2019, 78, 15-21.	3.3	17
105	Inhibition of Transglutaminase 2 as a Potential Host-Directed Therapy Against Mycobacterium tuberculosis. <i>Frontiers in Immunology</i> , 2019, 10, 3042.	4.8	13
106	Putting in Harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for Multidrug-Resistant Tuberculosis. , 2019, , .		3
107	Update on tuberculosis biomarkers: From correlates of risk, to correlates of active disease and of cure from disease. <i>Respirology</i> , 2018, 23, 455-466.	2.3	150
108	Managing latent tuberculosis infection and tuberculosis in children. <i>Pulmonology</i> , 2018, 24, 106-114.	2.1	31

#	ARTICLE	IF	CITATIONS
109	Impact of antiretroviral and tuberculosis therapies on CD4 + and CD8 + HIV/M. tuberculosis-specific T-cell in co-infected subjects. <i>Immunology Letters</i> , 2018, 198, 33-43.	2.5	21
110	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 70</i> 24, S10-S20.	6.0	139
111	Development of Potent Inhibitors of the <i>Mycobacterium tuberculosis</i> Virulence Factor Zmp1 and Evaluation of Their Effect on Mycobacterial Survival inside Macrophages. <i>ChemMedChem</i> , 2018, 13, 422-430.	3.2	43
112	Transglutaminase type 2 plays a key role in the pathogenesis of <i>Mycobacterium tuberculosis</i> infection. <i>Journal of Internal Medicine</i> , 2018, 283, 303-313.	6.0	23
113	Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2097-2111.	2.0	4
114	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 2427.	4.8	43
115	Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children. <i>Journal of Infection</i> , 2018, 77, 526-533.	3.3	30
116	Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. <i>Scientific Reports</i> , 2018, 8, 15626.	3.3	23
117	Can we predict tuberculosis cure? What tools are available?. <i>European Respiratory Journal</i> , 2018, 52, 1801089.	6.7	73
118	Clinical isolates of the modern <i>Mycobacterium tuberculosis</i> lineage 4 evade host defense in human macrophages through eluding IL-1 β -induced autophagy. <i>Cell Death and Disease</i> , 2018, 9, 624.	6.3	37
119	Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 501-512.	4.4	53
120	Diagnostic imaging of hepatic tuberculosis: case series. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 779-787.	1.2	11
121	Antitubercular and anti-inflammatory properties screening of natural products from <i>Plectranthus</i> species. <i>Future Medicinal Chemistry</i> , 2018, 10, 1677-1691.	2.3	5
122	Human CD4 T-Cells With a Naive Phenotype Produce Multiple Cytokines During <i>Mycobacterium Tuberculosis</i> Infection and Correlate With Active Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1119.	4.8	24
123	Interplay of DDP4 and IP-10 as a Potential Mechanism for Cell Recruitment to Tuberculosis Lesions. <i>Frontiers in Immunology</i> , 2018, 9, 1456.	4.8	33
124	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , 2018, 52, 1800946.	6.7	27
125	Evaluation of IP-10 in Quantiferon-Plus as biomarker for the diagnosis of latent tuberculosis infection. <i>Tuberculosis</i> , 2018, 111, 147-153.	1.9	42
126	Impaired IFN- γ -mediated signal in dendritic cells differentiates active from latent tuberculosis. <i>PLoS ONE</i> , 2018, 13, e0189477.	2.5	11

#	ARTICLE	IF	CITATIONS
127	The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. <i>International Journal of Infectious Diseases</i> , 2017, 56, 45-53.	3.3	37
128	Standard operating procedures for tuberculosis care. <i>European Respiratory Journal</i> , 2017, 49, 1700515.	6.7	6
129	Long-lasting tuberculous pleurisy. <i>European Respiratory Journal</i> , 2017, 49, 1700356.	6.7	3
130	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 183-192.	3.4	63
131	Differential Recognition of <i>Mycobacterium tuberculosis</i> Specific Epitopes as a Function of Tuberculosis Disease History. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 772-781.	5.6	39
132	A cell diagnostic test for cystic echinococcosis based on Antigen B peptides. <i>Parasite Immunology</i> , 2017, 39, e12499.	1.5	13
133	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. <i>Tuberculosis</i> , 2017, 106, 38-43.	1.9	89
134	Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 380-392.	0.7	26
135	Impact of pe_pgrs33 Gene Polymorphisms on <i>Mycobacterium tuberculosis</i> Infection and Pathogenesis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2017, 7, 137.	3.9	18
136	Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics. <i>Mediators of Inflammation</i> , 2017, 2017, 1-15.	3.0	93
137	Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages. <i>PLoS ONE</i> , 2017, 12, e0171358.	2.5	88
138	New synthetic lipid antigens for rapid serological diagnosis of tuberculosis. <i>PLoS ONE</i> , 2017, 12, e0181414.	2.5	18
139	Immune characterization of the HBHA-specific response in <i>Mycobacterium tuberculosis</i> -infected patients with or without HIV infection. <i>PLoS ONE</i> , 2017, 12, e0183846.	2.5	31
140	Tuberculosis Biomarkers: From Diagnosis to Protection. <i>Gastroenterology Insights</i> , 2016, 8, 6568.	1.2	129
141	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. <i>European Respiratory Journal</i> , 2016, 48, 1751-1763.	6.7	165
142	Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 55-61.	2.4	20
143	Influence of anti-TNF immunogenicity on safety in rheumatic disease: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 3-10.	2.4	15
144	Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit. <i>International Journal of Mycobacteriology</i> , 2016, 5, S25-S26.	0.6	12

#	ARTICLE	IF	CITATIONS
145	Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 35-54.	2.4	62
146	Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 11-34.	2.4	235
147	The best of respiratory infections from the 2015 European Respiratory Society International Congress. <i>ERJ Open Research</i> , 2016, 2, 00049-2016.	2.6	0
148	Preliminary data on precision of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 48, 955-956.	6.7	10
149	First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. <i>Journal of Infection</i> , 2016, 73, 588-597.	3.3	101
150	Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices. <i>European Respiratory Journal</i> , 2016, 48, 808-817.	6.7	75
151	Use of several immunological markers to model the probability of active tuberculosis. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 86, 169-171.	1.8	19
152	Preventing and controlling tuberculosis among refugees in Europe: more is needed. <i>European Respiratory Journal</i> , 2016, 48, 272-274.	6.7	19
153	First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. <i>European Respiratory Journal</i> , 2016, 48, 1411-1419.	6.7	119
154	Blood and urine inducible protein 10 as potential markers of disease activity. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1554-1561.	1.2	44
155	Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 344-352.	2.7	23
156	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
157	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	6.7	34
158	First independent evaluation of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 47, 1587-1590.	6.7	87
159	KLRG1 and PD-1 expression are increased on T-cells following tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults. <i>Tuberculosis</i> , 2016, 97, 163-171.	1.9	24
160	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	3.4	45
161	Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment. <i>PLoS Pathogens</i> , 2016, 12, e1005687.	4.7	138
162	Diagnostic Values of the QuantiFERON-TB Gold In-Tube Assay Carried out in China for Diagnosing Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2015, 10, e0121021.	2.5	10

#	ARTICLE	IF	CITATIONS
163	Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children. PLoS ONE, 2015, 10, e0138952.	2.5	37
164	Blood or Urine IP-10 Cannot Discriminate between Active Tuberculosis and Respiratory Diseases Different from Tuberculosis in Children. BioMed Research International, 2015, 2015, 1-11.	1.9	47
165	Granzyme A as a potential biomarker of Mycobacterium tuberculosis infection and disease. Immunology Letters, 2015, 166, 87-91.	2.5	13
166	False-negative interferon- γ release assay results in active tuberculosis: a TBNET study. European Respiratory Journal, 2015, 45, 279-283.	6.7	36
167	IL-4 specific-response in whole blood associates with human Cystic Echinococcosis and cyst activity. Journal of Infection, 2015, 70, 299-306.	3.3	32
168	Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmunity Reviews, 2015, 14, 503-509.	5.8	150
169	Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis. Journal of Infection, 2015, 71, 526-533.	3.3	54
170	A side-by-side comparison of T cell reactivity to fifty-nine Mycobacterium tuberculosis antigens in diverse populations from five continents. Tuberculosis, 2015, 95, 713-721.	1.9	35
171	Immune Status and Serial Quantiferon-TB Gold In-Tube Screening for Latent Mycobacterium tuberculosis Infection Among HIV-Infected Persons in a Country With a Low Tuberculosis Incidence. Journal of Infectious Diseases, 2015, 211, 1852-1853.	4.0	5
172	Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis. Clinical Infectious Diseases, 2015, 60, 432-437.	5.8	75
173	Risk Assessment of Tuberculosis in Contacts by IFN- γ Release Assays. A Tuberculosis Network European Trials Group Study. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1176-1184.	5.6	101
174	Towards tuberculosis elimination: an action framework for low-incidence countries. European Respiratory Journal, 2015, 45, 928-952.	6.7	608
175	Discordance between the QuantiFERON-TB Gold In-Tube and Tuberculin Skin Test: need for a further step?. European Respiratory Journal, 2015, 46, 1506-1509.	6.7	2
176	Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts. PLoS Neglected Tropical Diseases, 2015, 9, e0004209.	3.0	27
177	Granulocytic Myeloid Derived Suppressor Cells Expansion during Active Pulmonary Tuberculosis Is Associated with High Nitric Oxide Plasma Level. PLoS ONE, 2015, 10, e0123772.	2.5	67
178	A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multi-Centric Study (2006-2008); Evaluation of Serological Assays Based on PGL-Tb1 and ESAT-6/CFP10 Antigens for TB Diagnosis. PLoS ONE, 2014, 9, e96367.	2.5	12
179	Restarting Biologics and Management of Patients with Flares of Inflammatory Rheumatic Disorders or Psoriasis During Active Tuberculosis Treatment. Journal of rheumatology Supplement, The, 2014, 91, 78-82.	2.2	17
180	The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics. Journal of rheumatology Supplement, The, 2014, 91, 11-16.	2.2	50

#	ARTICLE	IF	CITATIONS
181	Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2014, 44, 23-63.	6.7	256
182	HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF- α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis. <i>International Journal of Rheumatology</i> , 2014, 2014, 1-9.	1.6	57
183	Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. <i>Journal of Infection</i> , 2014, 69, 533-545.	3.3	90
184	Biologics and Tuberculosis Risk: The Rise and Fall of an Old Disease and Its New Resurgence. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 1-3.	2.2	8
185	Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 47-55.	2.2	89
186	Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1168-1176.	5.6	196
187	Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor- α (TNF- α) Targeted Biologics and Recently Licensed TNF- α Inhibitors: Data from Clinical Trials and National Registries. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 56-64.	2.2	80
188	Performance of the Tuberculin Skin Test and Interferon- γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches. <i>Journal of rheumatology Supplement, The</i> , 2014, 91, 24-31.	2.2	80
189	High urine IP-10 levels associate with chronic HCV infection. <i>Journal of Infection</i> , 2014, 68, 591-600.	3.3	26
190	IFN γ /TNF α specific-cells and effector memory phenotype associate with active tuberculosis. <i>Journal of Infection</i> , 2013, 66, 475-486.	3.3	100
191	<i>Mycobacterium tuberculosis</i> -specific CD8 ⁺ T cells are functionally and phenotypically different between latent infection and active disease. <i>European Journal of Immunology</i> , 2013, 43, 1568-1577.	2.9	172
192	Autophagy in <i>Mycobacterium tuberculosis</i> infection: A passepartout to flush the intruder out?. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 335-343.	7.2	30
193	Serial QuantiFERON TB-Gold in-tube testing during LTBI therapy in candidates for TNFi treatment. <i>Journal of Infection</i> , 2013, 66, 346-356.	3.3	33
194	Cystic Echinococcosis in a Single Tertiary Care Center in Rome, Italy. <i>BioMed Research International</i> , 2013, 2013, 1-9.	1.9	19
195	TB elimination: a dream or a reality? Key lessons from the ERS external course in Dubrovnik, Croatia. <i>Breathe</i> , 2013, 9, 458-461.	1.3	0
196	A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multicentric Study (2006-2008). Evaluation of QuantiFERON-TB Gold in Tube for TB Diagnosis. <i>PLoS ONE</i> , 2013, 8, e73579.	2.5	15
197	MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. <i>Journal of Clinical Investigation</i> , 2013, 123, 4836-4848.	8.2	245
198	miRNA Signatures in Sera of Patients with Active Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2013, 8, e80149.	2.5	70

#	ARTICLE	IF	CITATIONS
199	Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. <i>Clinical Infectious Diseases</i> , 2012, 54, 853-861.	5.8	25
200	The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2012, 40, 990-1013.	6.7	211
201	Specific T Cells Restore the Autophagic Flux Inhibited by <i>Mycobacterium tuberculosis</i> in Human Primary Macrophages. <i>Journal of Infectious Diseases</i> , 2012, 205, 1425-1435.	4.0	44
202	Screening for latent infection with <i>Mycobacterium tuberculosis</i> : a plea for targeted testing in low endemic regions. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 231-234.	3.1	6
203	ESX-1 dependent impairment of autophagic flux by <i>Mycobacterium tuberculosis</i> in human dendritic cells. <i>Autophagy</i> , 2012, 8, 1357-1370.	9.1	237
204	A Toolbox for Tuberculosis Diagnosis: An Indian Multicentric Study (2006-2008): Microbiological Results. <i>PLoS ONE</i> , 2012, 7, e43739.	2.5	12
205	Tbnet " Collaborative research on tuberculosis in Europe. <i>European Journal of Microbiology and Immunology</i> , 2012, 2, 264-274.	2.8	15
206	Tuberculosis in Sheltered Homeless Population of Rome: An Integrated Model of Recruitment for Risk Management. <i>Scientific World Journal</i> , The, 2012, 2012, 1-7.	2.1	16
207	Janus-faced liposomes enhance antimicrobial innate immune response in <i>Mycobacterium tuberculosis</i> infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E1360-8.	7.1	60
208	IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. <i>Journal of Infection</i> , 2012, 65, 49-59.	3.3	61
209	Omics and single molecule detection: the future of TB diagnostics. , 2012, , 144-153.		1
210	Interferon- γ release assays for the diagnosis of latent <i>Mycobacterium tuberculosis</i> infection: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2011, 37, 88-99.	6.7	490
211	Methylated HBHA Produced in <i>M. smegmatis</i> Discriminates between Active and Non-Active Tuberculosis Disease among RD1-Responders. <i>PLoS ONE</i> , 2011, 6, e18315.	2.5	72
212	A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with <i>M. tuberculosis</i> . <i>Tuberculosis</i> , 2011, 91, 260-267.	1.9	113
213	IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. <i>BMC Infectious Diseases</i> , 2011, 11, 135.	2.9	74
214	Detection of Pulmonary tuberculosis: comparing MR imaging with HRCT. <i>BMC Infectious Diseases</i> , 2011, 11, 243.	2.9	54
215	Interferon- γ release assays for the diagnosis of latent <i>Mycobacterium tuberculosis</i> infection. <i>European Respiratory Journal</i> , 2011, 38, 1238-1239.	6.7	2
216	Higher Frequency of T-Cell Response to <i>M. tuberculosis</i> Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood. <i>PLoS ONE</i> , 2011, 6, e27539.	2.5	54

#	ARTICLE	IF	CITATIONS
217	IFN- γ , but not IP-10, MCP-2 or IL-2 response to RD1 selected peptides associates to active tuberculosis. <i>Journal of Infection</i> , 2010, 61, 133-143.	3.3	57
218	IP-10 detection in urine is associated with lung diseases. <i>BMC Infectious Diseases</i> , 2010, 10, 333.	2.9	65
219	Detection of interleukin-2 in addition to interferon- γ discriminates active tuberculosis patients, latently infected individuals, and controls. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1282-1284.	6.0	92
220	Bronchoalveolar lavage immunodiagnosis for tuberculosis suspects in Europe and Africa. <i>Thorax</i> , 2010, 65, 842-842.	5.6	1
221	Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection. <i>European Respiratory Journal</i> , 2010, 35, 619-626.	6.7	73
222	Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. <i>European Respiratory Journal</i> , 2010, 36, 135-142.	6.7	119
223	Do IFN- γ -release assays predict the risk of TB? New evidence from a study on patients with silicosis. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 1105-1108.	4.4	3
224	Quantitative Pulmonary T-Cell Responses for the Diagnosis of Active Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 289-290.	5.6	2
225	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
226	Is IP-10 an Accurate Marker for Detecting M. tuberculosis-Specific Response in HIV-Infected Persons?. <i>PLoS ONE</i> , 2010, 5, e12577.	2.5	73
227	Bronchoalveolar Lavage Enzyme-linked Immunospot for a Rapid Diagnosis of Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 666-673.	5.6	125
228	QuantIFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. <i>European Respiratory Journal</i> , 2009, 33, 586-593.	6.7	130
229	LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. <i>European Respiratory Journal</i> , 2009, 33, 956-973.	6.7	487
230	New tools for detecting latent tuberculosis infection: evaluation of RD1-specific long-term response. <i>BMC Infectious Diseases</i> , 2009, 9, 182.	2.9	51
231	Cytometric detection of antigen-specific IFN- γ /IL-2 secreting cells in the diagnosis of tuberculosis. <i>BMC Infectious Diseases</i> , 2009, 9, 99.	2.9	74
232	Characterization of regulatory T cells identified as CD4+CD25 ^{high} CD39+ in patients with active tuberculosis. <i>Clinical and Experimental Immunology</i> , 2009, 156, 463-470.	2.6	78
233	Response to M. tuberculosis selected RD1 peptides in Ugandan HIV-infected patients with smear positive pulmonary tuberculosis: a pilot study. <i>BMC Infectious Diseases</i> , 2008, 8, 11.	2.9	39
234	Use of Whole-Blood Samples in In-House Bulk and Single-Cell Antigen-Specific Gamma Interferon Assays for Surveillance of Mycobacterium tuberculosis Infections. <i>Vaccine Journal</i> , 2008, 15, 327-337.	3.1	27

#	ARTICLE	IF	CITATIONS
235	Update on clinical research of tuberculosis: a report from the European Respiratory Society. Expert Review of Respiratory Medicine, 2008, 2, 707-711.	2.5	0
236	Do human $\gamma\delta$ T cells respond to M tuberculosis protein antigens?. Blood, 2008, 112, 4776-4777.	1.4	4
237	Accuracy of Immunodiagnostic Tests for Active Tuberculosis Using Single and Combined Results: A Multicenter TBNET-Study. PLoS ONE, 2008, 3, e3417.	2.5	88
238	Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. International Journal of Tuberculosis and Lung Disease, 2008, 12, 146-51.	1.2	68
239	T Cell Responses to Commercial Mycobacterium tuberculosis--Specific Antigens in HIV-Infected Patients. Clinical Infectious Diseases, 2007, 45, 1652-1654.	5.8	10
240	Should Individuals Who Are Tuberculin Skin Test Negative and Positive to RD1 γ IFN- γ Assay Receive Preventive Therapy?. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 198a-199.	5.6	5
241	Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respiratory Research, 2007, 8, 5.	3.6	54
242	Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clinical and Experimental Immunology, 2007, 150, 91-98.	2.6	59
243	A Two-Step Approach for Screening Contacts of Active Tuberculosis. Infection, 2007, 35, 122-123.	4.7	2
244	Utilizzo di nuovi test immunologici nella diagnostica dell'infestazione da M. tuberculosis. Microbiologia Medica, 2006, 21, .	0.1	0
245	Accuracy of an immune diagnostic assay based on RD1 selected epitopes for active tuberculosis in a clinical setting: a pilot study. Clinical Microbiology and Infection, 2006, 12, 544-550.	6.0	78
246	Region of Difference 1 Antigen-Specific CD4+Memory T Cells Correlate with a Favorable Outcome of Tuberculosis. Journal of Infectious Diseases, 2006, 194, 984-992.	4.0	113
247	Selected RD1 Peptides for Active Tuberculosis Diagnosis: Comparison of a Gamma Interferon Whole-Blood Enzyme-Linked Immunosorbent Assay and an Enzyme-Linked Immunospot Assay. Vaccine Journal, 2005, 12, 1311-1316.	3.1	80
248	Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. International Journal of STD and AIDS, 2005, 16, 515-517.	1.1	33
249	Genetic Confirmation of Quinine-Resistant Plasmodium falciparum Malaria Followed by Postmalaria Neurological Syndrome in a Traveler from Mozambique. Journal of Clinical Microbiology, 2004, 42, 5424-5426.	3.9	17
250	Use of a T Cell-Based Assay for Monitoring Efficacy of Antituberculosis Therapy. Clinical Infectious Diseases, 2004, 38, 754-756.	5.8	203
251	Inhibition of HIV-1 Replication in Monocyte-Derived Macrophages by Mycobacterium tuberculosis. Journal of Infectious Diseases, 2004, 189, 624-633.	4.0	39
252	HIV/HCV co-infection: putting the pieces of the puzzle together. Cell Death and Differentiation, 2003, 10, S25-S26.	11.2	14

#	ARTICLE	IF	CITATIONS
253	Identification of Early Secretory Antigen Target-6 Epitopes for the Immunodiagnosis of Active Tuberculosis. <i>Molecular Medicine</i> , 2003, 9, 105-111.	4.4	49
254	Different Cytokine Production and Effector/Memory Dynamics of $\hat{I}^{\pm}I^{2+}$ or $\hat{I}^{\beta}I^{+}$ T-Cell Subsets in the Peripheral Blood of Patients with Active Pulmonary Tuberculosis. <i>International Journal of Immunopathology and Pharmacology</i> , 2003, 16, 247-252.	2.1	29
255	Identification of early secretory antigen target-6 epitopes for the immunodiagnosis of active tuberculosis. <i>Molecular Medicine</i> , 2003, 9, 105-111.	4.4	19
256	Acute Human Immunodeficiency Virus Replication Causes a Rapid and Persistent Impairment of $\hat{V}I^{39}\hat{V}I^{2}$ T Cells in Chronically Infected Patients Undergoing Structured Treatment Interruption. <i>Journal of Infectious Diseases</i> , 2002, 186, 847-850.	4.0	46
257	Lack of CD27 \hat{a} ~CD45RA \hat{a} ~ $\hat{V}I^{39}\hat{V}I^{2+}$ T Cell Effectors in Immunocompromised Hosts and During Active Pulmonary Tuberculosis. <i>Journal of Immunology</i> , 2002, 168, 1484-1489.	0.8	104
258	INTERLEUKIN (IL)-4 INHIBITS PHORBOL-ESTER INDUCED HIV-1 EXPRESSION IN CHRONICALLY INFECTED U1 CELLS INDEPENDENTLY FROM THE AUTOCRINE EFFECT OF ENDOGENOUS TUMOUR NECROSIS FACTOR- \hat{I}^{\pm} , IL-1 \hat{I}^{2} , AND IL-1 RECEPTOR ANTAGONIST. <i>Cytokine</i> , 2002, 17, 28-35.	3.2	10
259	The Loss of CMV-Specific CD27 \hat{a} ~ T-Cell Effectors in a Patient with Recurrences of CMV Retinitis Is Independent of HIV-1 Viremia. <i>Infection</i> , 2002, 30, 323-325.	4.7	4
260	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). <i>Vaccine</i> , 2001, 19, 2862-2877.	3.8	135
261	Prevalence, Incidence and Correlates of HHV-8/KSHV Infection and Kaposi's Sarcoma in Renal and Liver Transplant Recipients. <i>Journal of Infection</i> , 2001, 43, 195-199.	3.3	97
262	Clearance of Human Herpesvirus 8 from Blood and Regression of Leukopenia \hat{a} ~Associated Aggressive Classic Kaposi \hat{a} ~ $\hat{T}M$ s Sarcoma during Interferon \hat{a} ~ \hat{I}^{\pm} Therapy: A Case Report. <i>Clinical Infectious Diseases</i> , 2001, 33, 1782-1785.	5.8	7
263	Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. <i>Nature Medicine</i> , 1999, 5, 643-650.	30.7	288
264	Alpha Interferon Inhibits Human Herpesvirus 8 (HHV-8) Reactivation in Primary Effusion Lymphoma Cells and Reduces HHV-8 Load in Cultured Peripheral Blood Mononuclear Cells. <i>Journal of Virology</i> , 1999, 73, 4029-4041.	3.4	70
265	Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. <i>Blood</i> , 1999, 93, 4044-58.	1.4	149
266	The In Vitro Induction of Human Immunodeficiency Virus (HIV) Replication in Purified Protein Derivative \hat{a} ~Positive HIV \hat{a} ~Infected Persons by Recall Antigen Response to <i>Mycobacterium tuberculosis</i> Is the Result of a Balance of the Effects of Endogenous Interleukin \hat{a} ~ \hat{I}^{\pm} and Proinflammatory and Antiinflammatory Cytokines. <i>Journal of Infectious Diseases</i> , 1998, 177, 1332-1338.	4.0	59
267	HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous \hat{a} ~chemokines and the viral inductive effects of other endogenous cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 14076-14081.	7.1	119
268	Modulation of endogenous IL-1 beta and IL-1 receptor antagonist results in opposing effects on HIV expression in chronically infected monocytic cells. <i>Journal of Immunology</i> , 1996, 156, 3501-8.	0.8	27
269	Effect of <i>Mycobacterium tuberculosis</i> on HIV replication. Role of immune activation. <i>Journal of Immunology</i> , 1996, 157, 1271-8.	0.8	280
270	Cross-linking of CD30 induces HIV expression in chronically infected T cells. <i>Immunity</i> , 1995, 2, 587-596.	14.3	78

#	ARTICLE	IF	CITATIONS
271	Effect of cellular differentiation on cytokine-induced expression of human immunodeficiency virus in chronically infected promonocytic cells: dissociation of cellular differentiation and viral expression. <i>Journal of Virology</i> , 1995, 69, 2540-2546.	3.4	29
272	Analysis of Natural Killer (NK) Cell Subsets Defined by the Expression of Two Novel Surface Antigens (EB6 and GL183) in AIDS and AIDS-Related Conditions. <i>Clinical Immunology and Immunopathology</i> , 1994, 70, 198-205.	2.0	25
273	The Chronically Infected Promonocytic Cell Line U1: A Model of HIV Expression Regulated by Cytokines. <i>ImmunoMethods</i> , 1993, 3, 50-55.	0.8	11
274	Diagnosis and treatment of latent tuberculosis infection. , 0, , 381-398.		1
275	Biological Therapies and Tuberculosis Infection in Dermatology. , 0, , 1-5.		0